FS Bancorp (FSBW) Form 4: CEO granted options and restricted stock on 08/15/2025
Rhea-AI Filing Summary
Joseph C. Adams, Director and CEO of FS Bancorp, Inc. (FSBW), reported equity awards and option grants on 08/15/2025. He was awarded 3,788 restricted shares under the 2018 Equity Incentive Plan, which vest 25% per year beginning 08/15/2026. He was also granted 21,572 stock options with an exercise price of $40.14 and an expiration date of 08/15/2035; these options vest 25% per year beginning 08/15/2026. Additionally, a separate transaction shows 3,317 shares disposed at $40.14, and beneficial ownership following the transactions is reported as 138,592 shares (direct) and 17,818 shares
Positive
- Alignment with long‑term incentives: Awards vest over four years, tying compensation to future performance.
- Transparent pricing: Options set at a $40.14 exercise price consistent with the reported transaction price.
Negative
- Potential dilution: Grants total 25,360 shares/equivalents (restricted shares plus options underlying 21,572 shares) which will dilute if vested and exercised.
- Sale of shares: Director sold 3,317 shares, reducing direct holdings though beneficial ownership remains substantial.
Insights
TL;DR: CEO received time‑vested restricted stock and options; transaction is routine for executive compensation.
The filing documents routine equity compensation for the CEO/Director under the company's 2018 Equity Incentive Plan: restricted shares and long‑dated options that vest over four years starting 08/15/2026. The awards align executive pay with long‑term shareholder value by tying realized gains to future share performance and continued service. The filing also discloses a contemporaneous sale of 3,317 shares at $40.14, reducing direct holdings modestly while leaving substantial reported beneficial ownership. No change to control arrangements or accelerated vesting is indicated in the form.
TL;DR: Equity grants are significant in size but structured with standard four‑year vesting and a market exercise price.
The CEO was granted 21,572 options exercisable at $40.14 that expire in 2035 and 3,788 restricted shares, both vesting 25% annually beginning 08/15/2026. The option exercise price equals the reported sale price per share in the Form 4, indicating grants were priced at market on the transaction date. Vesting and ten‑year option term are typical for long‑term incentives; the grants will dilute existing shareholders only as they vest/exercise. The sale of 3,317 shares at $40.14 slightly offsets direct holdings but does not materially change reported beneficial ownership totals.